Scarica l'app Stockscreener
7.11
11.90%
-0.96
Dopo l'orario di chiusura:
7.25
0.14
+1.97%
Precedente Chiudi:
$8.07
Aprire:
$7.69
Volume 24 ore:
6.67M
Relative Volume:
2.17
Capitalizzazione di mercato:
$869.55M
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-1.2974
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
-23.63%
1M Prestazione:
-29.53%
6M Prestazione:
-65.40%
1 anno Prestazione:
-74.15%
Intervallo 1D:
$6.975
$7.83
Intervallo di 1 settimana:
$6.975
$9.36
Portata 52W:
$6.975
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
7.11 | 869.55M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
Intellia Focuses on Pipeline Development Amid Stiff Competition - TradingView
Contact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA) - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - GlobeNewswire Inc.
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (NTLA) - Seeking Alpha
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - Marketscreener.com
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class ... - Bluefield Daily Telegraph
Levi & Korsinsky Notifies Shareholders of Intellia - GlobeNewswire
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication - Yahoo Finance
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Intellia Therapeutics, Inc. Shareholders are Reminded of - GlobeNewswire
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA - TradingView
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire
Intellia stock plunges to 52-week low, hits $8.3 amid biotech rout - Investing.com India
NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TradingView
Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug - Seeking Alpha
Intellia Therapeutics Announces FDA Regenerative Medicine - GlobeNewswire
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - The Manila Times
Intellia gains FDA fast track for gene editing therapy - Investing.com
Intellia's Gene Therapy Scores Major FDA Breakthrough: Single-Dose ATTR Heart Treatment Advances - StockTitan
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm - TradingView
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
2025-03-24 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. LawsuitNTLA | NDAQ:NTLA | Press Release - Stockhouse Publishing
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Business Wire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds - Bluefield Daily Telegraph
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - PR Newswire
Intellia Therapeutics Investors Alert: Law Firm Seeks Shareholder Recovery for Potential Losses - Apna Kal
Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA) - ACCESS Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ROSEN, A RANKED AND LEADING FIRM, Encourages Intellia - GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR
(NTLA) Investment Report - Stock Traders Daily
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Yahoo Finance
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. LawsuitNTLA - PR Newswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Intellia - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders - PR Newswire
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):